Randomized trial · people

Mazdutide: 14.01% weight loss at 48 weeks in GLORY-1 (6 mg arm)

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large placebo-controlled trial, both weekly mazdutide doses led to more weight loss than placebo over 48 weeks, with gut side effects the most common problem and few people stopping because of them.

Kind
Randomized trial
Studied in
People
Number studied
610
Published
2025
Journal
N Engl J Med

What they tested

The team tested whether weekly mazdutide, a drug that acts on both the GLP-1 and glucagon receptors, lowers body weight in Chinese adults with overweight or obesity compared with placebo.

How the study was done

A phase 3, double-blind, placebo-controlled trial in China in 610 adults aged 18 to 75 with a BMI of at least 28, or a BMI of 24 to under 28 plus at least one weight-related health problem. People were randomly split into three equal groups to get 4 mg mazdutide, 6 mg mazdutide, or placebo (a dummy treatment) once a week for 48 weeks, with the main results judged at week 32.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking mazdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 32, body weight changed by -10.09% in the 4 mg arm, -12.55% in the 6 mg arm, and 0.45% on placebo, and 73.9%, 82.0%, and 10.5% of people lost at least 5% of their weight (P<0.001 for both doses against placebo). At week 48, the changes were -11.00%, -14.01%, and 0.30%, and 35.7%, 49.5%, and 2.0% lost at least 15%. Mazdutide improved every heart and metabolic measure the team had planned to track. Stomach and gut side effects were the most common and were mostly mild to moderate, and 1.5% (4 mg), 0.5% (6 mg), and 1.0% (placebo) stopped treatment because of side effects.

What it doesn’t show

The trial included only Chinese adults and ran for 48 weeks, so it does not show longer-term effects or results in other populations. It was funded by Innovent Biologics.

The paper

Ji et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025.

The compound

More studies on Mazdutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking mazdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo